Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical PBSC Transplant with Fludarabine, Cyclophosphamide, and TBI
NCT03333486Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Aug 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of peripheral blood stem cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), chronic myelogenous leukemia (CML), non-Hodgkin lymphoma (NHL), sponsored by Roswell Park Comprehensive Cancer Center. Started Dec 2017; status: terminated.
02
Drugs
peripheral blood stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndromes (MDS)chronic myelogenous leukemia (CML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03333486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333486.